TOP
STORY

Using advanced imaging technology that allowed them to spy on interactions among cells in the lymph nodes of living mice, scientists have identified a cell that is a key player in mounting the immune system’s defense against cancer. [Press release from University of California, San Francisco discussing online prepublication in Cancer Cell]
Press Release | Abstract | Graphical Abstract

The ability of Netrin-1 to interact with lymphocytes and its in-depth effects on leukocyte migration are poorly understood. Researchers profiled the mRNA and protein expression of known Netrin-1 receptors on human CD4+ T cells. [J Immunol]
Abstract

The growth inhibitory effects of bufadienolide compounds were investigated in two intractable cancer cells, a human glioblastoma cell line U-87 and a pancreatic cancer cell line SW1990. [Oncol Rep]
Abstract

Based on preclinical and human studies, researchers hypothesized that, in addition to its antiangiogenic properties, sorafenib may beneficially reduce the extent of the immunosuppressive network in hepatocellular carcinoma (HCC) patients. [JCI Insight]
Full Article | Press Release

The growing number of diverse targets for which hydrogen sulfide (H2S) serves as a gasotransmitter has been extensively reviewed elsewhere. The authors discuss current emerging evidence that H2S regulates mesenchymal stem cell and T-cell functions. [J Dent Res]
Abstract

Visit our
reviews
page to see a complete list of reviews in
the immune regulation research field.

Targazyme, Inc. announced that it has enrolled the first patient in a Phase I/II TZ 101-treated regulatory T cell clinical study. This Phase I/II clinical study will evaluate the efficacy and safety of TZ101-treated regulatory T cells in the prevention and treatment of acute and chronic graft-versus-host-disease in stem cell transplants. [Targazyme, Inc. (Marketwired)]
Press Release

The Alliance for Lupus Research, the Lupus Research Institute, and the S.L.E. Lupus Foundation announced the merger of the three organizations to form the Lupus Research Alliance. [The Alliance for Lupus Research]
Press Release

Hansa Medical AB announced the acquisition of UK based Immago Biosystems Ltd, a University of Oxford-spinout focused on the enhancement of antibody based cancer therapies using antibody-modulating enzymes. [Hansa Medical AB]
Press Release

Britain’s hopes of leading the world in revolutionary therapies that regenerate damaged body parts are under threat because the NHS drugs watchdog cannot properly evaluate them, a report says. [The Guardian]
Editorial | Report

Three weeks after UK voters chose to leave the European Union, the country has a new prime minister, Theresa May — and a revamped administration that is poised to change science’s place in government. [Nature News]
Editorial

The political and economic crisis in Venezuela continues to worsen. As the price of oil — the country’s major export — has fallen, Venezuela has struggled to pay for imported goods while maintaining socialist economic policies put in place by former president Hugo Chávez. [Nature News]
Editorial

Younger biomedical researchers—those between 35 and 39—are about as likely to win funding from the National Institutes of Health (NIH) as their elders, according to a study published in Cell Stem Cell. This finding seems to upend the widespread impression that older scientists have higher success rates than their juniors in the competition for grants. [Science Careers]
Editorial | Article

Lawmakers don’t usually acknowledge that the bills they introduce in Congress have little chance of passage in the near future, but that’s what Representative Bill Pascrell, Jr., (D-NJ) did in a phone press conference to discuss the H-1B and L-1 Visa Reform Act of 2016, which he introduced in the House of Representatives. Still, “we’re trying to build momentum” and raise awareness of the need to reform these high-skill guest worker visa programs, he said. [Science Careers]
Editorial